10-Q: Enzon Q3 Loss, Viskase Merger Extended, Ownership Shift

Enzon Pharmaceuticals reported a net loss for Q3 2025 and the nine months ended September 30, 2025, while announcing an amendment to its merger agreement with Viskase Companies, Inc., extending the closing date and adjusting ownership.

Summary

• Net loss for the three months ended September 30, 2025, was $824,000, a decline from net income of $254,000 for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $2,338,000, compared to net income of $850,000 for the same period in 2024.
• Royalties and milestone revenues were $0 for both the three and nine months ended September 30, 2025, down from $0 and $26,000 respectively in 2024.
• Interest and dividend income decreased by 24% to $496,000 for the three months and by 22% to $1,494,000 for the nine months ended September 30, 2025, primarily due to reduced cash balances and lower interest rates.
• Transaction expenses related to the Viskase merger were $1,075,000 for the quarter and $2,801,000 for the nine months ended September 30, 2025.
• Cash and cash equivalents decreased by $3,603,000 from $46,859,000 at December 31, 2024, to $43,256,000 at September 30, 2025.
• The merger agreement with Viskase Companies, Inc. was amended on October 24, 2025, extending the termination date to March 31, 2026, and adjusting post-merger ownership to 45% for current Enzon stockholders and 55% for Viskase stockholders.
• A 1-for-100 reverse stock split for Enzon common stock is planned prior to the merger.
• The Section 382 Rights Agreement was amended to expire on December 31, 2025, as required by the merger agreement.
• The company's stock moved from OTCQX to OTCQB on August 12, 2025, due to its bid price falling below $0.10 for 30 consecutive days.

Sentiment

Score: 3

Explanation: The company reported significant net losses, zero royalty revenue, and a decline in cash and equity. Its stock was demoted to OTCQB. While the Viskase merger provides a strategic direction, it is not yet finalized, involves substantial transaction costs, and will result in significant dilution for current common shareholders, reflecting a challenging current financial and operational state.

Positives

• The Hart-Scott-Rodino (HSR) waiting period for the Viskase merger was granted early termination on July 15, 2025, indicating progress in regulatory approvals.
• Management believes the merger should not limit the company's substantial Net Operating Loss (NOL) carryforwards under Section 382 of the IRC, potentially preserving significant tax assets.
• General and administrative expenses decreased by 35% to $229,000 for the three months ended September 30, 2025, compared to the prior year, excluding merger-related costs.
• Existing cash and cash equivalents are believed to be sufficient to fund operations through November 2026 if the merger is not consummated.

Negatives

• Reported a net loss of $824,000 for the three months and $2,338,000 for the nine months ended September 30, 2025, a significant decline from net income in the prior year periods.
• Zero royalty and milestone revenues for the three and nine months ended September 30, 2025, highlighting the cessation of its historical revenue stream.
• Interest and dividend income decreased by 24% and 22% for the three and nine-month periods, respectively, due to reduced cash balances and lower interest rates.
• Significant transaction expenses of $1,075,000 for the quarter and $2,801,000 for the nine months ended September 30, 2025, impacted profitability.
• Cash and cash equivalents decreased by $3,603,000 during the nine months ended September 30, 2025.
• Total stockholders (deficit) equity turned negative, reaching $(923,000) at September 30, 2025, from $3,008,000 at December 31, 2024.
• The company's stock was delisted from OTCQX and moved to OTCQB due to its bid price falling below $0.10 for 30 consecutive days, indicating poor market performance.
• The Series C Preferred Stock dividend was accrued at 5% accretion for the nine months ended September 30, 2025, instead of a cash dividend, increasing the liquidation preference and further impacting common shareholder equity.
• Current Enzon stockholders will experience immediate dilution and hold a minority share (approximately 45%) in the combined company post-merger.

Risks

• The conditions to the closing of the Viskase merger may not be satisfied, including the failure to obtain necessary approvals for the proposed transaction.
• Uncertainties exist regarding the timing of the consummation of the merger and the ability of Viskase to timely deliver the financial statements required by the Merger Agreement.
• Anticipated benefits of the proposed transaction, including revenues, expenses, earnings, and the anticipated tax treatment of the combination, may not be realized.
• Potential litigation relating to the proposed merger could be instituted against Enzon, Viskase, or their respective officers or directors.
• Possible disruptions from the merger could harm Enzon or Viskase's respective businesses.
• Potential adverse reactions or changes to relationships with customers, suppliers, employees, or other parties resulting from the uncertainty during the pendency of the merger.
• The company may be unsuccessful in its strategy to fully utilize its Net Operating Losses (NOLs) and other tax assets, as the Section 382 rules are complex and there is no assurance the company's view is correct regarding NOL preservation.
• Sources of revenue are limited, and only limited revenue and profitability are expected for the foreseeable future prior to the merger.
• Rights to receive royalties on sales of PegIntron and other drug products have expired, and no future royalties from other sources are anticipated.
• The company has reallocated all employment responsibilities and outsourced all corporate functions, making it more dependent on third parties to perform these functions.
• The price of the company's common stock has been, and may continue to be, volatile, and market liquidity is low due to trading on the OTCQB market.
• The declaration of dividends is within the discretion of the Board of Directors, subject to Series C Preferred Stock requirements and the consent of Viskase under the merger agreement.
• The Section 382 rights plan, designed to protect NOLs, must be terminated prior to the merger, removing this protection.
• Anti-takeover provisions in charter documents and under Delaware corporate law may make it more difficult to acquire the company.
• The terms of outstanding Series C Preferred Stock and the issuance of additional series of preferred stock may adversely affect the rights of common stockholders.
• The interests of significant stockholders, such as Icahn Enterprises Holdings L.P. and its affiliates, may conflict with the interests of other stockholders due to their substantial ownership and voting power.
• If the merger is not completed, substantial costs incurred will not be recovered, and further costs may be incurred, adversely affecting business, financial results, and operations.
• If the merger is consummated or a Change of Control occurs, holders of Series C Preferred Stock (other than IEH and affiliates) have the right to demand redemption, which would negatively impact available cash.
• Unpredictability and severity of effects from geopolitical events, economic conditions, inflationary pressures, trade wars, and global supply chain issues could adversely affect the business.

Future Outlook

The company is primarily focused on completing its merger with Viskase Companies, Inc., which is anticipated to close by March 31, 2026. Post-merger, Enzon Pharmaceuticals, Inc. will change its name to Viskase Holdings, Inc., and Viskase will operate as a wholly-owned subsidiary. The company expects to effect a 1-for-100 reverse stock split prior to the merger. If the merger is not consummated, the company will continue as a public company acquisition vehicle, with existing cash expected to fund operations through November 2026, but with de minimis future royalty revenues. The company believes the merger should not limit its substantial NOL carryforwards, but this is subject to complex tax rules and no assurance is given.

Management Comments

• "Enzon cannot assure you that it will receive any future royalties or milestone payments."
• "Management of the Company will continue to assess the need for this valuation allowance and will make adjustments when or if appropriate."
• "In the opinion of management, the ultimate disposition of these matters [legal claims] will not have a material effect on the Companys consolidated financial position, results of operations, or liquidity."
• "We believe that our existing cash and cash equivalents on hand will be sufficient to fund our operations, at least, through November 2026, if the Merger is not consummated."
• "Enzon believes that the Merger pursuant to the terms of the Merger Agreement, as amended by the Merger Agreement Amendment, should not limit its net operating loss (NOL) carryforwards and other tax attributes under Section 382 of the Internal Revenue Code of 1986, as amended (IRC). However, the Section 382 rules are complex and there is no assurance that the Companys view is correct."
• "Our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2025, the Companys disclosure controls and procedures were effective."

Industry Context

Enzon Pharmaceuticals has transitioned from a pharmaceutical company with royalty streams to a public company acquisition vehicle, reflecting a common strategy for companies with limited ongoing operations to seek new business through mergers. The proposed merger with Viskase Companies, Inc. indicates a pivot away from the pharmaceutical sector towards Viskase's industry (implied to be different from pharma). The involvement of Icahn Enterprises Holdings L.P. suggests a strategic move by a significant activist investor to restructure and potentially unlock value from Enzon's cash and tax assets by combining it with Viskase. The delisting from OTCQX to OTCQB reflects the company's current low market valuation and limited trading activity, typical for a shell company awaiting a transformative transaction.

Comparison to Industry Standards

• The company's current state as a 'public company acquisition vehicle' with 'no clinical operations and limited corporate operations' and 'de minimis' royalty revenues is not comparable to active pharmaceutical companies.
• Its financial performance, characterized by net losses and declining cash, is indicative of a non-operating entity incurring costs related to its acquisition strategy rather than generating revenue from core business.
• The planned 1-for-100 reverse stock split is a common measure for companies with low stock prices to meet listing requirements or improve market perception, often seen in companies undergoing significant restructuring or mergers.
• The substantial NOL carryforwards ($101 million federal, $23.2 million NJ state) are significant assets for a company of this size, and their preservation is a key driver for the merger structure, a common strategy in corporate reorganizations involving distressed or non-operating entities.
• The involvement of Icahn Enterprises Holdings L.P. as a controlling shareholder and facilitator of the merger is consistent with activist investor strategies to leverage existing public shells for new ventures.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any lawsuit or proceeding which, in the opinion of management, is likely to have a material adverse effect on the company or its business.

Related Party Transactions

• Icahn Enterprises Holdings L.P. (IEH) and its affiliates, as significant stockholders of both Enzon and Viskase, entered into an amendment to the Support Agreement. IEH agreed to deliver written consents for the merger and exchange its Series C Preferred Stock for common stock prior to the merger. This is a related party transaction due to IEH's substantial ownership in both entities.

Stakeholder Impact

• Shareholders (Common Stock): Will experience immediate and significant dilution, holding approximately 45% of the combined company post-merger. A 1-for-100 reverse stock split will reduce the number of shares outstanding. Their influence on management will be limited due to IEH's substantial voting power.
• Shareholders (Series C Preferred Stock): Icahn Enterprises Holdings L.P. and its affiliates will exchange their Series C Preferred Stock for common stock based on liquidation preference and 20-Day VWAP. Other Series C holders will have the option to demand redemption upon change of control (merger consummation), which could impact the combined company's cash.
• Employees: The filing mentions that the company has 'reallocated all employment responsibilities and outsourced all corporate functions,' implying minimal direct employee impact from Enzon's side, but the merger will integrate Viskase's operations.
• Customers/Suppliers: No direct impact mentioned for Enzon's historical business, but Viskase's customers and suppliers will be affected by the change in ownership and corporate structure.
• Creditors: The company's cash position and potential for future profitability post-merger could affect creditors, but no specific impact is detailed.

Next Steps

• Enzon intends to file a registration statement on Form S-4 with the SEC, containing a consent solicitation statement and prospectus relating to the Viskase merger.
• Enzon stockholders must approve the merger.
• The company will effect a 1-for-100 reverse stock split prior to the effective time of the merger.
• The Section 382 Rights Agreement must be terminated prior to the effective time of the merger (currently set to expire December 31, 2025).
• If the merger has not closed by December 31, 2025, Enzon may seek to further extend the Final Expiration Date under the Rights Agreement.
• The Board will determine whether to declare a cash dividend on Series C Preferred Stock at the end of 2025, requiring Viskase's consent under the merger agreement.
• Management will continue to assess the need for the valuation allowance on deferred tax assets.

Key Dates

Recommendation

The company is in a transitional phase, moving from a non-operating shell to a combined entity with Viskase. While the current financial results are poor (losses, no revenue, declining cash), the proposed merger offers a clear strategic path and potential for future operations. The extension of the merger deadline and the involvement of a major investor like Icahn Enterprises suggest a commitment to closing the deal. However, significant dilution for existing common shareholders, the uncertainty of merger completion, and the complexity of NOL preservation warrant a cautious 'hold' rather than a 'buy' until the merger is finalized and the combined entity's operational and financial prospects become clearer. A 'sell' would be premature given the potential for the merger to unlock value from the shell status and tax assets.

Keywords

Enzon Pharmaceuticals, Viskase Companies, Merger Agreement, 10-Q Filing, Quarterly Report, SEC Filing, Financial Results, Net Operating Losses, NOLs, Section 382, Reverse Stock Split, OTC Markets, OTCQB, Series C Preferred Stock, Acquisition Vehicle, Corporate Governance, Icahn Enterprises, Financial Performance